MET and non-small cell lung carcinoma: This phase Ib dose-expansion study in 38 c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic NSCLC showed that BPI-9016M was well-tolerated in each dose cohort, and exhibited potential antitumor activity in those with c-MET overexpression or MET exon 14 skipping mutation.